

03-15-2001

Q60688

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office



3ET

101637435

To the Director - U.S. Patent and Trademark Office

Attached original documents or copy thereof.

1. Name of conveying party(ies):

Zvia AGUR, Sarel FLEISHMANN, Kirill
SKOMOROVSKI and Moshe VARDI

Additional name(s) of conveying party(ies) attached?

☐ yes

☒ no

3. Nature of Conveyance:

☒ Assignment

☐ Merger

☐ Security Agreement

☐ Change of Names

☐ Other

Execution Dates: December 01, 2000 and
November 30, 2000

2. Name and address of receiving party(ies)?

OPTIMATA LTD.
Suite 1, Business Centre
Dan Tel Aviv Hotel
99 Hayarkon Street
Tel Aviv 63432 ISRAEL



Additional name(s) & address(es) attached?

☐ yes

☒ no

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)
09/691,053

B. Patent No.(s)

Additional numbers attached?

☐ Yes

☒ No

5. Name and address of party to whom correspondence
concerning document should be mailed:

SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Suite 800
Washington, D.C. 20037-3213

6. Total number of applications and registration involved:
1

7. Total Fee (37 CFR 3.41): \$40.00

☒ Enclosed. Please charge any underpayment in
connection with this Assignment to Deposit Account No. 19-4880.

☐ Authorized to be charged to Deposit Account

8. Deposit Account No.

19-4880

40E

DO NOT WRITE IN THIS SPACE

9. Statement and Signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the
original document.

William H. Mandir

Reg. No. 32,156

March 8, 2001

Date

TOTAL NUMBER OF PAGES COMPRISING COVER SHEET, ATTACHMENTS AND DOCUMENT: 2

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Director - U.S. Patent and Trademark Office

Box Assignment

Washington, D.C. 20231

Assignment

Whereas, We, Zvia AGUR of 20 Zichron-Yaacov St., Tel Aviv, Israel, Sarel FLEISHMANN of 12 Ha'Shirion St., Nes-Ziona, Israel, Kirill SKOMOROVSKI of 23 Amos-Daniely St., Rehovot, Israel, and Moshe VARDI of 29 Ha'Nassi Ha'Rishon St., Rehovot, Israel, respectively, hereinafter called assignors, have invented certain improvements in

SYSTEM AND METHODS FOR OPTIMIZED DRUG DELIVERY AND PROGRESSION OF DISEASED AND NORMAL CELLS

and executed an application for Letters Patent of the United States of America therefor on _____; and

Whereas, OPTIMATA LTD., Suite 1, Business Centre, Dan Tel Aviv Hotel, 99 Hayarkon Street, Tel Aviv 63432, Israel (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

We, the above named assignors, hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. §119, and we request the Commissioner of Patents to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

We hereby authorize and request our attorneys SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC of 2100 Pennsylvania Avenue, NW, Washington, DC 20037-3212 to insert here in parentheses (Application number 09/691,053, filed October 19, 2000) the filing date and application number of said application when known.

Zvia AGUR

Date: 1.12.2000 s/

Sarel FLEISHMANN

Date: 1.12.2000 s/

Kirill SKOMOROVSKI

Date: 1.12.2000 s/

Moshe VARDI

Date: 30/11/00 s/

Moshe Vardi

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

8/92